Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib Resistance

IIIb/IV NSCLC With T790M Positive Mutations Failed to Osimertinib Therapy Clinical Trial

Official title: Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib Resistance：a Phase II,Muti-center, Single Arm Study

Status Recruiting

Clinical Trial Summary

This is an open-label, single-arm, multi-center, phase II exploratory study that evaluates the efficacy and safety of Toripalimab injection (JS001) combined with Pemetrexed and Anlotinib as a second-line treatment for patients with T790M positive Non-Small Cell Lung Cancer (IIIb / IV ) after Osimertinib resistance.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• IIIb/IV NSCLC With T790M Positive Mutations Failed to Osimertinib Therapy

• NCT number: NCT04316351
• Study type: Interventional
• Source: Guangzhou Institute of Respiratory Disease
• Contact: zhou cheng zhi, Doctor
• Phone: (+86)13560351186
• Email: doctorzcz@163.com
• Status: Recruiting
• Phase: Phase 2
• Start date: April 1, 2020
• Completion date: April 1, 2022